Pharmaceutical intermediates
Repotrectinib Intermediates
2 pharmaceutical intermediates for Repotrectinib. Indication: Solid tumors; non-small cell lung cancer.
About Repotrectinib
- Originator
- Turning Point Therapeutics Inc
- Indication
- Solid tumors; non-small cell lung cancer
- Approved Date
- 06/11/2024
- NCE Patent
- 11/15/2028
- DS/DP
- 01/23/2035
Available intermediates
2 intermediates currently listed for Repotrectinib. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| Ethyl 5-chloropyrazolo[1,5-a]pyrimidine-3-carboxylate | 1224944-77-7 | / | / |
| Pentafluorophenyldiphenylphosphinate | 138687-69-1 | / | / |
Other programs under R
Building toward Repotrectinib?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →